Skip To Main Content
Steven Nissen on Muck Rack

Steven Nissen

As seen in: Annals of Internal Medicine, National Institutes of Health, Color Research & Application, Nature, The Wall Street Journal, Memory Studies, PLOS Medicine, heart, U.S. News and World Report, JAMA (The Journal of the American Medical Association), JAMA: Journal of the American Medical Association and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Steven

Contact Steven, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Bempedoic Acid and Venous Thromboembolism Risk Among Statin-Intolerant Patients : A Post Hoc Analysis of the CLEAR Outcomes Randomized Clinical Trial

|
By Bernardo F Spiazzi, Danielle Brennan, Carolina P. Zingano, Heather Powell, Stephen Nicholls Verified, Steven Nissen, Luke J. Laffin
| JAMA Cardiology
Supplement 1. Supplement 2. Statistical Analysis Plan Supplement 3. eAppendix. Supplemental Methods eFigure 1. Flow of Participants Through the CLEAR Outcomes Trial eFigure 2. Subgroup Analyses for Venous Thromboembolism eTable 1. Cross-Censoring Sensitivity Analysis for Venous Thromboembolism and Major Adverse Cardiovascular Events eTable 2.
Open in Who Shared Issue with article?

Author Correction: Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial

|
By Stephen Nicholls Verified, Adam Nelson, Marc Ditmarsch, John J. P. Kastelein, Christie M. Ballantyne, Kausik K. Ray, Ann Marie Navar, Steven Nissen, Anne C. Goldberg, Liam R. Brunham, Erin Wuerdeman, Annie Neild, Douglas Kling, Andrew Hsieh, Julie Butters, Brian A. Ference, Ulrich Laufs, Maciej Banach, Roxana Mehran, Alberico L Catapano, Michael Szarek, Violeta Balinskaite, Michael Davidson
| Nature Verified
Correction to: Nature Medicine https://doi.org/10.1038/s41591-025-04179-4, published online 27 February 2026.
Open in Who Shared Issue with article?

Tirzepatide Outperforms Dulaglutide in Cardiorenal Outcomes, With Steven Nissen, MD

|
By Steven Nissen
| consultantlive.com
Tirzepatide treatment resulted in a substantial reduction in a broad 6-component composite of cardiovascular and kidney endpoints compared to dulaglutide, according to a post hoc analysis of the SURPASS-CVOT trial.1 These data were presented at the American College of Cardiology (ACC) Scientific Sessions 2026 in New Orleans, Louisiana, by Steven Nissen, MD, chief academic officer of the Heart and Vascular Institute at the Cleveland Clinic and professor of medicine at the Lerner College of...
Open in Who Shared View Duplicates (2) Issue with article?
See all 197 licensed articles (207 Total)